Standard BioTools: Neutral Stance Amid Revenue Contraction Risk and M&A-Dependent Growth Outlook

TD Cowen analyst Kyle Boucher maintained a Hold rating on Standard BioTools yesterday and set a price target of $1.35.

Kyle Boucher has given his Hold rating due to a combination of factors including a solid quarter but a challenging backdrop. The company modestly exceeded expectations in both instruments and consumables and issued 2026 revenue guidance slightly above consensus, yet that outlook still implies year-over-year contraction amid persistent weakness in academic end markets that make up a large share of Standard BioTools’ demand.

At the same time, Boucher notes that management is emphasizing cost controls and has implemented additional savings to support a path toward positive adjusted EBITDA and cash flow by late 2026. With the SomaLogic sale completed and roughly $550 million in cash on the balance sheet, the investment case now hinges on how effectively that capital is deployed for acquisitions, so he prefers to stay neutral until there is clearer evidence that M&A can translate into durable growth and an improved valuation profile.

Based on the recent corporate insider activity of 44 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of LAB in relation to earlier this year.